What is Veru?
Veru Inc. is a late clinical stage biopharmaceutical company based in Miami, Florida. The company is dedicated to the development and commercialization of novel treatments for a range of conditions including cardiometabolic diseases, inflammatory diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS). Veru's pipeline features enobosarm, a selective androgen receptor modulator aimed at addressing muscle loss in patients undergoing weight loss therapy with GLP-1 drugs, and for metastatic breast cancer. Additionally, the company is developing sabizabulin, an anti-inflammatory agent targeting atherosclerotic coronary artery disease and high-risk hospitalized patients with viral lung infections. Veru operates through Commercial and Research and Development segments, with a portfolio that includes medicines for prostate cancer and urology specialty pharmaceuticals, alongside sexual health products marketed via its Urev division.
How much funding has Veru raised?
Veru has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Veru
PPP
Public-Private Partnership
What's next for Veru?
With its substantial total funding and a recent strategic investment, Veru Inc. is poised to advance its late-stage clinical development programs. The company's focus on significant unmet medical needs in areas like cardiometabolic diseases, oncology, and viral infections, coupled with its innovative drug candidates such as enobosarm and sabizabulin, suggests a strategic push towards commercialization and market penetration. This capital will likely fuel further clinical trials, regulatory submissions, and potential expansion of its commercial infrastructure, reinforcing its position in the competitive biopharmaceutical landscape.
See full Veru company page
